This event has passed. View key highlights below.
At the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Xyzagen Founder and CEO Christopher Crean presented preclinical research on behalf of Optigo Biotherapeutics focused on advancing long-acting anti-VEGF therapies for retinal disease.
Christopher Crean, who also serves as Head of Preclinical Development for Optigo Biotherapeutics, presented a scientific poster in the session “AMD: New Drugs, Delivery Systems, and Mechanisms of Action.” The poster highlighted preclinical findings from Optigo’s long-acting retinal delivery platform designed to reduce the burden of frequent intravitreal injections for patients with neovascular eye diseases.
Poster Details
Title: Anchoring of Bispecific Anti-VEGF Molecules to Vitreous Components Extends Half-Life and Duration of Efficacy
Session: AMD: New Drugs, Delivery Systems, and Mechanisms of Action
Presentation Date: May 6, 2025
The research demonstrated that anchoring bispecific anti-VEGF molecules to native vitreous proteins resulted in significant half-life extension and durable efficacy in both rabbit and rat VEGF challenge models. These findings support the potential for extended dosing intervals of six to nine months—an important step toward improving treatment adherence and patient quality of life.
Executive Quote
“Reducing injection frequency while maintaining efficacy has long been a goal in retinal therapeutics,” said Christopher Crean. “This work that we have helped manage for Optigo represents a key step forward in achieving more durable anti-VEGF treatments with real-world impact for patients.”
Final Takeaways
Xyzagen supported this work through integrated preclinical pharmacology, pharmacokinetics, and study design expertise—illustrating how translational science can accelerate the development of next-generation ophthalmic therapies.
If you’re interested in how Xyzagen can support your preclinical development program in ophthalmology, pharmacology, pharmacokinetics, or related therapeutic areas such as neurology, we’d welcome the opportunity to connect. Contact us today.
About Xyzagen, Inc.
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late stage clinical noncompartmental PK, PopPK and Quantitative Medicine. Our knowledge in pharmacology and pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. We’re a boutique organization which allows for small clients to work directly with experts during their critical decisions.
Media Contact:
Christopher Crean
Founder & CEO
Xyzagen, Inc.
Phone: (919)-762-2072
Email: [email protected]
